Efficacy of chemical shift MRI for differentiating diffuse red bone marrow reconversion and hematological malignancies

Burcu AKMAN1*, Hatice Ayça ATA KORKMAZ1, Ahmet SARI2*
1Department of Radiology, Kanuni Research and Education Hospital, Trabzon, Turkey
2Department of Radiology, Faculty of Medicine, Farabi Hospital, Karadeniz Technical University, Trabzon, Turkey

Background/aim: The main purpose of our study was to determine the efficacy of chemical shift imaging (CSI) for differentiating diffuse red bone marrow reconversion (RBMR) and hematological malignancies. We also aimed to calculate the cut-off value for these entities with similar imaging features in routine magnetic resonance (MR) sequences.

Materials and methods: A total of 54 patients were included: 17 patients (31.4%) with hematological malignancies (group 1), 16 patients (29.6%) with RBMR (group 2), and 21 patients (38.0%) with no clinical and hematological malignancies (control group). Patients with no pathological data or completed two-year follow-up and children were excluded from the study. An experienced radiologist on MRI evaluated the images blindly for final diagnosis. Pathologic results were determined as gold standard. Regions of interests (ROI) were placed on the vertebrae in CSI and signal intensity ratios (SIR) were calculated. The cut-off value was calculated using receiver operating characteristic (ROC) analysis.

Results: SIR values were 0.97 ± 0.16, 0.69 ± 0.31 and 0.28 ± 0.35 (P < 0.001) for GI, G2, and G3, respectively. The cut-off value was 0.82 (P < 0.001). The sensitivity rate was 83.3% (AUC: 58%–96%), specificity was 87% (AUC: 58–98).

Conclusion: CSI may be a valuable diagnostic tool for differentiating diffuse RBMR and hematological malignancies.

Key words: Magnetic resonance imaging, in-phase, out-of-phase, chemical shift, reconversion, hematological malignancy, red bone marrow

1. Introduction

Normal bone marrow contains water, fat, and cellular elements. The red bone marrow (RB) contains 40% of water (free and bound), 20% of protein, and 40% (25%–50%) of fat. In contrast, the yellow bone marrow (YB) contains 15% of water, 5% of protein, and 80% of fat (1–4). In newborns, the bone marrow consists mainly of active RB. After the infantile period, the RB begins to transform into YB. When the active bone marrow is not able to meet the increased hematopoiesis required by the body, YB converts to RB, and this process is called reconversion (3–7). The causes of reconversion can be classified under medical and nonmedical conditions. Medical conditions include obesity, respiratory disorders, diabetes, anemias, patients receiving granulocyte colony stimulating factor therapy, chemotherapy, and radiotherapy. Nonmedical conditions include heavy smoking and practicing sports requiring high oxygen such as marathon running or freediving (2,5–7).

Magnetic resonance imaging (MRI) is an ideal noninvasive imaging modality for evaluating bone marrow (1,4). Routine spinal MR protocols include T1 weighted (T1W), T2 weighted (T2W), and short tau inversion recovery (STIR) sequences (3). Due to its high water content, RB has an intermediate low signal intensity in T1W and low signal intensity in T2W (2,4,6).

In T1W, abnormal bone marrow and RB have a diffusely equal or lower intensity than the adjacent muscle or disc. In RBW reconversion and malignancies, we can see the high signal intensity in STIR and T2 weighted fat suppressed images (2,6). Therefore, it is near impossible to distinguish hyperplastic red marrow from other bone marrow replacement disorders while observing only conventional MRI techniques (1). Due to its similar imaging features, leukemia, lymphoma, and breast cancer metastases with widespread bone involvement are difficult to distinguish from RBW (3).

Chemical shift MRI is commonly used for liver and adrenal glands imaging for detecting lipid content and characterizing lesions (8–11). Also, chemical shift MRI is
the best sequence for differentiating malignant and benign bone marrow lesions (3). Chemical shift MRI is based on the different oscillation frequency of water and fat protons (8,10). Due to the presence of fat and water in the normal bone marrow, bone marrow signal intensity is suppressed in the out-of-phase. In malignant infiltration of the bone marrow, tumoral structures are replaced by fat components of the bone marrow and no regression occurs (10–12).

The main purpose of our study was to determine the efficacy of chemical shift imaging (CSI) in the differential diagnosis of red bone marrow reconversion (RBMR) and diffuse bone marrow involvement in hematological malignancies. We also aimed to calculate the cut-off value for the differential diagnosis of RBMR and hematological malignancies.

2. Materials and methods
2.1. Study population
After ethical committee approval (Karadeniz Technical University Faculty of Medicine Assessment of the Scientific Research Committee Approval Number: 2010/7), we recruited a total of 54 patients (32 female and 22 male), 17 patients (31.4%) with hematological malignancies (group 1), 16 patients (29.6%) with RBMR (group 2), and 21 patients (38.0%) with no clinical and hematological malignancies (control group).

The vertebral bone marrow signal intensity of the hematological malignancy cases (group 1) and cases with RBMR reconversion (group 2) was diffusely equal to or lower than those of the neighboring muscle or disc in T1-weighted images. In the control group (group 3), vertebral bone marrow signal intensity in T1-weighted images was higher than those of the neighboring muscle or discs. Patients with no pathological data, completed two-year follow-up, and children were excluded from the study. Pathological diagnosis was accepted as the gold standard method.

2.2. MR technique
Siemens Magnetom (Symphony and Aera; Siemens Healthcare, Erlangen, Germany) 1.5T MRI systems and a dedicated standard spine coil were used in this study.

The protocols used were sagittal T1W turbo spin-echo (TSE) (TR / TE: 343/14) and axial–sagittal T2-W TSE (TR / TE: 4000/106) sequences. No contrast agents were applied during the examination.

Vertebral bone marrow chemical shift MR imaging was completed in approximately 40–50 s.

2.3. MR image analysis
A neuroradiologist with 10 years of experience evaluated the thoracolumbar MRIs of all the groups. The radiologist was blinded to the final diagnosis and clinical history. In all the groups the T1W and CSI images of each patient were evaluated in one special workstation (Leonardo, Siemens).

At first, ROIs were placed on the vertebrae bodies’ midsections in both sequences of CSI in at least five vertebrae and then SI measurements were analyzed (Figure 1). The mean area of circular ROIs was determined as 0.8–1.1 cm². Mean SI values of the vertebrae in out-of-phase and in-phase sequences were calculated. Signal intensity ratio (SIR) was calculated with the obtained values according to the “SIR = out-of-phase signal intensity value / in-phase signal intensity value” formula which was used in previous studies (12–14) to distinguish benign from malignant bone marrow involvement. The cut-off value for discriminating malignancies was calculated using ROC analysis.

2.4. Statistical analysis
In this study, the Chi-square test was used for counting data. The Kolmogorov–Smirnov test was used to evaluate the values obtained by the ROI measurements to determine if they have a normal distribution or not. Student-t-test was used to evaluate the two parameters that matched normal distribution, and ANOVA test was used to evaluate the remaining parameters. Mann–Whitney U test was used for two nonparametric tests, and Kruskal–Wallis was used for more than two parameters. Pearson (parametric) and Spearman (nonparametric) analysis were used for correlation analysis. P < 0.05 values were considered statistically significant. All analyzes were done using the SPSS 22.0 statistical program (IBM Corp., Armonk, NY, USA) (15).

3. Results
Demographic characteristics, hemoglobin (Hb) levels, clinical diagnoses, BM biopsy results, and SIR values were shown in Table 1–4.
Figure 1. SI measurements on out-of-phase and in-phase sequences.

Table 1. Demographic characteristics, hemoglobin levels, clinical diagnoses, SIR values, and biopsy results of group 1.

| Case | Sex  | Age | Weight | Hb level (mg/dl) | History of hematological malignancy | SIR  | **BM biopsy results |
|------|------|-----|--------|------------------|--------------------------------------|------|---------------------|
| 1    | Male | 61  | 73     | 7                | *(+)*                                | 1.1  | CLL+ NHL            |
| 2    | Male | 68  | 78     | 10               | *(+)*                                | 1.32 | B cell lymphoma     |
| 3    | Male | 68  | 80     | 9                | *(+)*                                | 0.72 | MM                  |
| 4    | Female | 38 | 85     | 12               | *(+)*                                | 0.99 | ALL                 |
| 5    | Female | 62 | 86     | 8                | *(+)*                                | 0.99 | CLL                 |
| 6    | Male | 48  | 79     | 9                | *(+)*                                | 0.8  | MM                  |
| 7    | Male | 74  | 64     | 8                | *(+)*                                | 0.86 | MM                  |
| 8    | Male | 68  | 71     | 7                | *(+)*                                | 0.83 | MM                  |
| 9    | Male | 45  | 68     | 8                | *(+)*                                | 1.06 | MM                  |
| 10   | Female | 44 | 95     | 11               | *(+)*                                | 1.23 | MM                  |
| 11   | Female | 70 | 70     | 7                | *(+)*                                | 0.85 | MM                  |
| 12   | Female | 55 | 80     | 12               | *(+)*                                | 0.98 | MM                  |
| 13   | Female | 51 | 80     | 9                | *(+)*                                | 0.95 | B cell lymphoma     |
| 14   | Male  | 77  | 70     | 10               | *(+)*                                | 0.83 | MM                  |
| 15   | Male  | 52  | 72     | 7                | *(+)*                                | 1.02 | MM                  |
| 16   | Female | 21 | 50     | 9                | *(+)*                                | 1.2  | HL                  |
| 17   | Female | 42 | 51     | 8                | *(+)*                                | 0.86 | AML                 |

Hb: Hemoglobin, SIR: Signal intensity ratio, BM: Bone marrow, CLL: Chronic lymphocytic leukemia, NHL: Non–Hodgkin’s Lymphoma, MM: Multiple myeloma. ALL: Acute lymphoblastic leukemia.

*(+): Patient with history of hematological malignancy.

**: Bone marrow results at the time of MRI imaging.
In group 1 (hematological malignancies with diffuse bone marrow involvement) the vertebral bone marrow signal intensity was diffusely equal to or lower than the adjacent muscle or disc in T1-weighted images. In CSI, no signal loss was observed in the out-of-phase sequence compared to the in-phase sequence (Figure 2). The mean OP / IP SIRs of the cases were calculated as 0.97 ± 0.16. All the patients in group 1 had a result of pathologic bone marrow biopsy at the time of MRI imaging that revealed infiltration in accordance with the hematological malignancy.

In group 2 (cases with RBM reconvension) vertebral bone marrow signal intensity was diffusely equally or lower than the adjacent muscle or disc in T1-weighted images. In CSI of the 3 patients (18.25%), the signal loss was not observed in the out-of-phase sequence while in the remaining 13 (81.25%) patient’s images, the signal loss was observed in the out-of-phase sequence compared to the in-phase sequence (Figure 3). In CSI, the mean OP / IP SIRs of the cases were calculated as 0.69 ± 0.31. All the patients in group 2 had a history of hematological malignancy; one patient had a history of T-cell lymphoma, one had an acute myelocytic leukemia (AML), and one had an acute lymphoblastic leukemia (ALL). In these three cases, bone marrow biopsy at the time of MRI showed no infiltration, and hypercellular bone marrow was detected.

In group 3 (control group), the vertebral bone marrow signal intensity in T1-weighted images was higher than the adjacent muscle or disc. CSI in all cases showed a significant loss of signal in the out-of-phase sequence compared to the in-phase sequence (Figure 4). The mean OP / IP SI ratios of the patients were calculated as 0.28 ± 0.35.

In our study, according to ROC analysis, AUC was calculated to be 0.828 (95%), CI (safety interval) was 0.647–0.989, P = 0.002. ROC analysis revealed a cut-off value of 0.82 for the differentiation of hematological malignancies from RBMR. Those with lower SIR values than the cut-off value were considered benign bone marrow, and those with higher values than the cut-off value were considered malignant bone marrow.

Table 2. Demographic characteristics, hemoglobin levels, clinical diagnoses, SIR values, and biopsy results of group 2.

| Case | Sex | Age | Weight | Hb level (mg/dl) | History of hematological malignancy | SIR | **BM biopsy results |
|------|-----|-----|--------|-----------------|-------------------------------------|-----|-------------------|
| 1    | Female | 23  | 54     | 13              | ***( - )**                           | 0.58| No BM biopsy Stable at follow-up |
| 2    | Female | 41  | 69     | 12              | ***( - )**                           | 0.8 | No BM biopsy Stable at follow-up |
| 3    | Female | 27  | 70     | 11              | ***( - )**                           | 0.67| No BM biopsy Stable at follow-up |
| 4    | Male   | 46  | 85     | 10              | ***( - )**                           | 0.5 | Hypercellular BM   |
| 5    | Female | 37  | 65     | 13              | ***( - )**                           | 0.81| Normocellular BM   |
| 6    | Male   | 61  | 70     | 10              | ***( - )**                           | 0.73| Hypercellular BM   |
| 7    | Female | 25  | 90     | 14              | ***( - )**                           | 0.59| No BM biopsy Stable at follow-up |
| 8    | Male   | 61  | 75     | 10              | ***( - )**                           | 0.65| No BM biopsy Stable at follow-up |
| 9    | Male   | 35  | 60     | 9               | ***( - )**                           | 1.22| Hypercellular BM   |
| 10   | Female | 39  | 88     | 7               | *(+)                                | 0.63| Hypercellular BM   |
| 11   | Male   | 34  | 70     | 7               | *(+)                                | 1.3 | Hypercellular BM   |
| 12   | Male   | 46  | 74     | 9               | *(+)                                | 1.16| Hypercellular BM   |
| 13   | Female | 54  | 78     | 13              | ***( - )**                           | 0.69| No BM biopsy Stable at follow-up |
| 14   | Female | 33  | 72     | 13              | ***( - )**                           | 0.27| No BM biopsy Stable at follow-up |
| 15   | Male   | 41  | 89     | 14              | ***( - )**                           | 0.21| No BM biopsy Stable at follow-up |
| 16   | Female | 51  | 60     | 11              | ***( - )**                           | 0.35| No BM biopsy Stable at follow-up |

Hb: Hemoglobin, SIR: Signal intensity ratio, BM: Bone marrow
*(+): Patients who had history of hematological malignancy.
**( )**: BM results at the time of MRI imaging.
**( - )**: Patient who had no history of hematological malignancy.
negative results. Three patients with high cut-off values in group 2 were determined as false positive results. Two of them were patients with hematological malignancies in remission (T-cell lymphoma and AML) and with hypercellular bone marrow biopsy results. One of the false positive patients had a transverse myelitis disease and no history of malignancies.

In group 2, the patient with ALL in remission, the SIR value was calculated as 0.63. This SIR value was lower than 0.82 and was consistent with the pathologic result.

For the cut-off value of 0.82, the sensitivity of our study was calculated as 83.3% (AUC: 58%–96%), the specificity of our study was calculated as 87% (AUC: 58–98), the negative predictive value of our study was calculated as 81% (AUC: 54%–95%), and finally the positive predictive value calculated was 88% (AUC: 62%–98%).

When the cut-off value was determined as 0.82, there was a statistically significant difference between the hematological malignancies and RBMR (P < 0.001) (Figure 5).

4. Discussion

BMR is a confusing entity in radiology due to its similar imaging features with hematological malignancies. Various diagnostic methods such as MRI, scintigraphy, PET, and

| Case | Sex | Age | Weight | Hb level (mg/dL) | History of hematological malignancy | SIR |
|------|-----|-----|--------|-----------------|-------------------------------------|-----|
| 1    | Female | 51  | 51     | 11              | ***( - )***                          | 0.2 |
| 2    | Female | 45  | 70     | 13              | ***( - )***                          | 0.3 |
| 3    | Female | 43  | 70     | 13              | ***( - )***                          | 0.3 |
| 4    | Male   | 35  | 68     | 13              | ***( - )***                          | 0.29|
| 5    | Female | 45  | 60     | 15              | ***( - )***                          | 0.48|
| 6    | Female | 40  | 75     | 12              | ***( - )***                          | 0.26|
| 7    | Female | 40  | 51     | 13              | ***( - )***                          | 0.31|
| 8    | Female | 29  | 49     | 12              | ***( - )***                          | 0.21|
| 9    | Male   | 45  | 60     | 14              | ***( - )***                          | 0.21|
| 10   | Male   | 33  | 80     | 14              | ***( - )***                          | 0.24|
| 11   | Female | 48  | 120    | 9               | ***( - )***                          | 0.39|
| 12   | Female | 49  | 70     | 14              | ***( - )***                          | 0.41|
| 13   | Male   | 45  | 71     | 14              | ***( - )***                          | 0.24|
| 14   | Male   | 31  | 76     | 14              | ***( - )***                          | 0.21|
| 15   | Female | 42  | 68     | 15              | ***( - )***                          | 0.21|
| 16   | Female | 50  | 68     | 14              | ***( - )***                          | 0.27|
| 17   | Female | 56  | 60     | 13              | ***( - )***                          | 0.26|
| 18   | Female | 33  | 60     | 13              | ***( - )***                          | 0.2  |
| 19   | Female | 51  | 83     | 12              | ***( - )***                          | 0.22|
| 20   | Male   | 58  | 71     | 13              | ***( - )***                          | 0.4  |
| 21   | Female | 56  | 90     | 13              | ***( - )***                          | 0.37|

Hb: Hemoglobin, SIR: Signal intensity ratio
***( - )***: Patient who had no history of hematological malignancy.

Table 4. Mean SIR values for each group

| Groups | Mean SIR values | SD   |
|--------|-----------------|------|
| Group 1 | 0.97            | ±0.16|
| Group 2 | 0.69            | ±0.31|
| Group 3 | 0.28            | ±0.35|

SIR: Signal intensity ratio, SD: Standard deviation
biopsy are used for differential diagnosis in hematology. However, scintigraphy and PET tests are not available in every health center and have high radiation doses.

CSI is a simple, noninvasive, and fast radiological imaging technique that can be applied in all MRI systems. The most important advantage is that it can detect a small amount of fat in a mixture of water and fat (16). In CSI, bone marrow signal intensity is suppressed in the out-of-phase due to the presence of both fat and water in healthy individuals. Secondary to malignant infiltration in the bone marrow, fatty components are replaced by tumoral structures and the expected suppression does not occur (10).

The major disadvantages of CSI include the inability to suppress signals from adipose tissue in the out-of-phase images and the difficulty of detecting small tumors embedded in fat. In addition, signal intensities from peripheral fat tissues may invalidate signal intensities of the tumor (16).

The first study on the use of CSI in bone marrow lesions was performed by Wismer GL et al. (17). To the best of our knowledge, there are no other studies focusing on the use of CSI for the differentiation of RBMR and diffuse bone marrow involvement in hematological malignancies. However, there are studies investigating the contribution of CSI in the differentiation of benign-malignant fractures in the bones (10,14,18) and in the differential diagnosis of focal bone lesions (12,13,19,20). In these studies, SIR values of neoplastic compression fractures and focal malignant lesions were found to be significantly higher than the SIR values of benign fractures and lesions.

In the present study, the malignant bone marrow SIR values were also significantly higher than the benign bone marrow SIR values. In previous studies, only focal bone marrow lesions were evaluated for the diagnostic value of CSI for differential diagnosis between malignant and benign lesions. In our study, we investigated the

Figure 2. A 51-year-old female patient, biopsy result of T8 vertebra consisting of B-cell lymphoma. (a) Thoracic vertebral bone marrow signal intensity was low in the sagittal T1W sequence compared to the adjacent disc. T8 vertebra had pathological fracture and epidural mass was shown at the same level. (b) The pathological fracture of the T8 vertebra and the epidural mass in the neighborhood were more prominent in the thoracic sagittal T2W sequence. In sagittal out-of-phase sequence (c) no signal loss was observed compared to the in-phase sequence (d) SIR was calculated as 0.95 on chemical shift sequences and higher than the cut off value.
Figure 3. A 60-year-old male patient had chronic disease anemia. Bone marrow biopsy was consistent with hypercellular bone marrow. (a) The vertebral bone marrow signal intensity in the lumbar sagittal T1W sequence is equal to those in T1W images compared to the adjacent disc. In the sagittal out-of-phase sequence (b), there was signal loss compared to the in-phase sequence (c). The SIR value is calculated as 0.73 and is consistent with benignity.

Figure 4. A 45-year-old woman with no history of chronic disease or malignancy with a normal hemoglobin value (control group). (a) In the sagittal T1W sequence of the lumbar vertebrae, the bone marrow signal intensity was higher than the adjacent disc and was normal. (b) In T2W sequence, vertebral bone marrow was homogeneous and no pathology was detected. In the sagittal out-of-phase sequence (c), there was marked loss of signal in the vertebral bone marrow compared to the in-phase sequence (d). The SIR value was calculated as 0.3 and was lower than the cut-off value. The patient was stable during clinical and radiological 2-year follow-up and no malignancy developed.
efficacy of CSI for the differential diagnosis of diffuse RBM reconversion and hematological malignancies with diffuse bone marrow involvement. Early et al. determined the cut-off value for differentiation of benign and malignant bone fractures as 0.80, and Disler et al. determined the cut-off value for differentiation focal bone lesions as 0.81 (13,18). According to our study results, the cut-off value was 0.82 for the differential diagnosis of hematological malignancies and RBMR. Lower SIR values determined benign bone marrow, and those with higher values were considered malignant bone marrow. In our two false negative MM cases in group 1, the result may be secondary to diffuse but heterogeneous vertebral bone marrow involvement.

The most important limitation of our study was the small sample size. Our second major limitation is the fact that all of the biopsies were performed from the iliac crests and not directly from the vertebrae except in one patient. Finally, the present study was a retrospective study; therefore, the SIRs values were not considered in the clinical management.

According to our study results, chemical shift MRI may be a valuable diagnostic tool for the differential diagnosis of hematological malignancies and benign disorders with RBM involvement when appropriate cut-off values are used. Further studies with larger series are required to enrich the findings of the present study.

Acknowledgment
This research was presented as an oral presentation in the 39th National Radiology Congress, Antalya, Turkey, 6–11 November 2018.

References
1. Vogler JB 3rd, Murphy WA. Bone marrow imaging. Radiology 1988; 168: 679–693.
2. Stoller DW. Magnetic Resonance Imaging in Orthopaedics and Sports Medicine. Vol 1. Philadelphia, PA, USA: Lippincott Williams & Wilkins, 2007.
3. Del Grande F, Farahani SJ, Carrino JA, Chhabra A. Bone marrow lesions: a systematic diagnostic approach. Indian J Radiol Imaging 2014; 24: 279.
4. Zhao F, Shen J, Yu X, Zhou H, Lu Z et al. Bone marrow reconversion mimicking pelvis metastases in a patient with rectal cancer: a pitfall on magnetic resonance images. Quant Imaging Med Surg 2018; 8: 621.
5. Swartz PG, Roberts CC. Radiological reasoning: bone marrow changes on MRI. AJR Am J Roentgenol 2009; 193: S1-S4.
6. Alyas F, Saifuddin A, Connell D. MR imaging evaluation of the bone marrow and marrow infiltrative disorders of the lumbar spine. Magn Reson Imaging Clin N Am 2007; 15: 199-219.

7. Malkiewicz A, Dziedzic M. Bone marrow reconversion-imaging of physiological changes in bone marrow. Pol J Radiol 2012; 77: 45.

8. Yazıcı Z, Doğan Ö, Yalçın R, Savcı G. Adrenal adenomların tanısında kimyasal şift mr görüntüleme: kalitatif değerlendirme. Uludağ Üniversitesi Tıp Fakültesi Dergisi 2002; 28: 17-21.

9. Xiao Z, Li J, Li C, Zhang Y, She D et al. Chemical shift MR imaging in the lumbar vertebra: the effect of field strength, scanner vendors and flip angles in repeatability of signal intensity index measurement. BMC Med Imaging 2016; 16: 64.

10. Ragab Y, Ema f, Yehida T, Mansour M, Abou-Zeid A et al. Differentiation of osteoporotic and neoplastic vertebral fractures by chemical shift [in-phase and out-of-phase] MR imaging. Eur J Radiol 2009; 72: 125-133.

11. Del Grande F, Subhawong T, Flammang A, Fayad L. Chemical shift imaging at 3 Tesla: effect of echo time on assessing bone marrow abnormalities. Skeletal Radiol 2014; 43: 1139-1147.

12. Costa FM, Canella C, Vieira FG, Vianna EM, Meohas W et al. The usefulness of chemical-shift magnetic resonance imaging for the evaluation of osteoid osteoma. Radiol Bras 2018; 51: 156-161.

13. Disler DG, McCauley TR, Ratner LM, Kesack CD, Cooper JA. In-phase and out-of-phase MR imaging of bone marrow: prediction of neoplasia based on the detection of coexistent fat and water. AJR Am J Roentgenol 1997; 169: 1439-1447.

14. Eito K, Waka S, Naoko N, Makoto A, Atsuko H. Vertebral neoplastic compression fractures: Assessment by dual-phase chemical shift imaging. J Magn Reson Imaging 2004; 20: 1020-1024.

15. IBM Corp. Released IBM SPSS Statistics for Windows, Version 22.0. Armonk, NY: IBM Corp. Vol Version 22.0. NY: IBM Corp.: Armonk; 2013.

16. Delfaut EM, Beltran J, Johnson G, Rousseau J, Marchandise X et al. Fat suppression in MR imaging: techniques and pitfalls. Radiograph. 1999; 19: 373-382.

17. Wismer GL, Rosen BR, Buxton R, Stark DD, Brady TJ. Chemical shift imaging of bone marrow: preliminary experience. Am J Roentgenol 1985;145:1031-7.

18. Erly WK, Oh ES, Outwater EK. The utility of in-phase/ opposed-phase imaging in differentiating malignancy from acute benign compression fractures of the spine. AJNR Am J Neuroradiol 2006; 27: 1183-1188.

19. Zajick Jr DC, Morrison WB, Schweitzer ME, Parellada JA, Carrino JA. Benign and malignant processes: normal values and differentiation with chemical shift MR imaging in vertebral marrow. Radiology 2005; 237: 590-596.

20. Kohl CA, Chivers FS, Lorans R, Roberts CC, Kransdorf MJ. Accuracy of chemical shift MR imaging in diagnosing indeterminate bone marrow lesions in the pelvis: review of a single institution's experience. Skeletal Radiol 2014; 43: 1079-1084.